Article

USE OF BLOOD PRODUCTS IN ONCOLOGICAL PATIENTS TREATED WITH RADIO AND CHEMOTHERAPY

Acta Medica Medianae 01/2008;

ABSTRACT

Retrospectively, we analyzed the use of blood products in Oncological Clinic of Clinical Center Nis in the period November 1st 2007-November 1st 2008, and also the influence of the treatment on degree of anemia and thrombocytopenia and use of blood products. None of the patients received the whole blood. In this period, 324 patients received the transfusion of blood components, 302 patients received 983 units of red cells (red blood cell concentrate, resuspended, washed, filtered), 17 patients received 5050 ml of platelets (single-donor concentrate or pooled platelet concentrate) and 5 patients received 2200 ml of fresh frozen plasma. An average use of red cell transfusion is 3,26 units, platelet concentrate 5,54, fresh frozen plasma 2 units per oncological patient who receives transfusion. The use of red cell units and platelet concentrate transfusion was adequate (91,85% of patients received transfusion of red cells when Hgb<70g/l, 89,2% of patients received platelet concentrate transfusion when platelet count was less than 20 x109/l). During radio and chemotherapy we noticed a decrease of hematological parameter values, whereas the experimental group patients were dependent on blood product transfusion. Statistically, a significant decrease of hemoglobin level and platelet count was observed in the patients treated only with radiotherapy, who are the greatest consumers of blood products.

Download full-text

Full-text

Available from: Ivica Pejcic